Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the drug for ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Biogen's stock underperformed in 2024 due to poor sales of Leqembi and declining multiple sclerosis revenues, despite efforts to diversify its pipeline. Leqembi's market struggles continue ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...